CYTR Share Price

Open 0.44 Change Price %
High 0.44 1 Day 0.00 0.00
Low 0.42 1 Week 0.03 7.50
Close 0.43 1 Month -0.17 -28.33
Volume 1035462 1 Year -0.14 -24.56
52 Week High 1.00
52 Week Low 0.36
CYTR Important Levels
Resistance 2 0.45
Resistance 1 0.44
Pivot 0.43
Support 1 0.42
Support 2 0.41
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
ASTI 0.00 0.00%
More..
NASDAQ USA Top Gainers Stocks
RITT 0.02 100.00%
LOCM 0.09 50.00%
NETE 0.72 44.00%
SCHS 0.04 33.33%
MRGE 0.55 30.95%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PGRX 0.05 25.00%
ESMC 0.12 20.00%
More..
NASDAQ USA Top Losers Stocks
DEER 0.00 -100.00%
CAFI 0.00 -100.00%
ORIG 24.00 -96.52%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CPWR 1.00 -60.00%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

CytRx Corporation (NASDAQ: CYTR)

CYTR Technical Analysis 5
As on 22nd Sep 2017 CYTR Share Price closed @ 0.43 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.51 & Strong Sell for SHORT-TERM with Stoploss of 0.57 we also expect STOCK to react on Following IMPORTANT LEVELS.
CYTR Target for September
1st Target up-side 0.78
2nd Target up-side 0.96
3rd Target up-side 1.13
1st Target down-side 0.28
2nd Target down-side 0.1
3rd Target down-side -0.07
CYTR Other Details
Segment EQ
Market Capital 47314736.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.cytrx.com
CYTR Address
CYTR
11726 San Vicente Boulevard
Suite 650
Los Angeles, CA 90049
United States
Phone: 310-826-5648
Fax: 310-826-6139
CYTR Latest News
Interactive Technical Analysis Chart CytRx Corporation ( CYTR NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on CytRx Corporation
CYTR Business Profile
CytRx Corporation (CytRx) is a biopharmaceutical research and development company specializing in oncology. The Company's oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. INNO-206 is the Company's tumor-targeted doxorubicin conjugate. On May 13, 2011, the Company sold all pre-clinical and clinical data, intellectual property rights and other assets relating to those compounds to Orphazyme ApS. During the year ended December 31, 2011, the Company sold of its 19% interest in SynthRx to ADVENTRX Pharmaceuticals.